Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1988 Jul;82(1):206–211. doi: 10.1172/JCI113571

Factor VIII-bypassing activity of bovine tissue factor using the canine hemophilic model.

D P O'Brien 1, A R Giles 1, K M Tate 1, G A Vehar 1
PMCID: PMC303495  PMID: 3134399

Abstract

The bleeding disorder of hemophilia A currently treated by replacement therapy of the missing coagulation factor, factor VIII, is frequently complicated by the development of neutralizing antibodies. The therapeutic potential of attenuated forms of the lipid-associated glycoprotein tissue factor, a known initiator of coagulation, was investigated as a factor VIII-by-passing activity. The protein moiety of tissue factor (Apo-TF) was partially purified and exhibited minimal procoagulant activity before relipidation in vitro. In pilot studies, Apo-TF injection into rabbits previously anticoagulated with an antibody to factor VIII was found to have a procoagulant effect. The efficacy of the material was further demonstrated when injection of Apo-TF in hemophilic dogs resulted in a normalization of the cuticle bleeding time. Little or no change in the blood parameters associated with disseminated intravascular coagulation was observed at lower doses, although mild to moderate effects were seen at higher doses. These data suggest a novel role for Apo-TF preparations as a potential therapeutic agent for hemophiliacs with antibodies to factor VIII once the potential thrombogenicity of such materials is evaluated.

Full text

PDF
206

Images in this article

209Image
on p.209

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abildgaard C. F. Hazards of prothrombin-complex concentrates in treatment of hemophilia. N Engl J Med. 1981 Mar 12;304(11):670–671. doi: 10.1056/nejm198103123041115. [DOI] [PubMed] [Google Scholar]
  2. Aronson D. L. There is no correlation between vitamin K dependent coagulant content and clinical effectiveness of activated and standard factor IX complex concentrates. Prog Clin Biol Res. 1984;150:243–250. [PubMed] [Google Scholar]
  3. Bach R., Nemerson Y., Konigsberg W. Purification and characterization of bovine tissue factor. J Biol Chem. 1981 Aug 25;256(16):8324–8331. [PubMed] [Google Scholar]
  4. Brackmann H. H., Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet. 1977 Oct 29;2(8044):933–933. doi: 10.1016/s0140-6736(77)90871-6. [DOI] [PubMed] [Google Scholar]
  5. Breen F. A., Jr, Tullis J. L. Prothrombin concentrates in treatment of Christmas disease and allied disorders. JAMA. 1969 Jun 9;208(10):1848–1852. [PubMed] [Google Scholar]
  6. Broze G. J., Jr, Leykam J. E., Schwartz B. D., Miletich J. P. Purification of human brain tissue factor. J Biol Chem. 1985 Sep 15;260(20):10917–10920. [PubMed] [Google Scholar]
  7. CLAUSS A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957 Apr;17(4):237–246. doi: 10.1159/000205234. [DOI] [PubMed] [Google Scholar]
  8. Carson S. D. Plasma high density lipoproteins inhibit the activation of coagulation factor X by factor VIIa and tissue factor. FEBS Lett. 1981 Sep 14;132(1):37–40. doi: 10.1016/0014-5793(81)80422-x. [DOI] [PubMed] [Google Scholar]
  9. Cederbaum A. I., Blatt P. M., Roberts H. R. Intravascular coagulation with use of human prothrombin complex concentrates. Ann Intern Med. 1976 Jun;84(6):683–687. doi: 10.7326/0003-4819-84-6-683. [DOI] [PubMed] [Google Scholar]
  10. Fukui H., Fujimura Y., Takahashi Y., Mikami S., Yoshioka A. Laboratory evidence of DIC under FEIBA treatment of a hemophilic patient with intracranial bleeding and high titre factor VIII inhibitor. Thromb Res. 1981 Apr 1;22(1-2):177–184. doi: 10.1016/0049-3848(81)90319-4. [DOI] [PubMed] [Google Scholar]
  11. Gatti L., Mannucci P. M. Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies. Thromb Haemost. 1984 Jul 29;51(3):379–384. [PubMed] [Google Scholar]
  12. Giles A. R. By what mechanisms could prothrombin complex concentrates promote factor VIII bypassing activity in vivo? Transfus Med Rev. 1987 Aug;1(2):131–137. doi: 10.1016/s0887-7963(87)70013-3. [DOI] [PubMed] [Google Scholar]
  13. Giles A. R., Nesheim M. E., Mann K. G. Studies of Factors V and VIII:C in an animal model of disseminated intravascular coagulation. J Clin Invest. 1984 Dec;74(6):2219–2225. doi: 10.1172/JCI111648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Giles A. R., Tinlin S., Greenwood R. A canine model of hemophilic (factor VIII:C deficiency) bleeding. Blood. 1982 Sep;60(3):727–730. [PubMed] [Google Scholar]
  15. Gomperts E. D., Jordan S., Church J. A., Sakai R., Lemire J. Induction of tolerance to factor VIII in a child with a high-titer inhibitor: in vitro and in vivo observations. J Pediatr. 1984 Jan;104(1):70–75. doi: 10.1016/s0022-3476(84)80592-2. [DOI] [PubMed] [Google Scholar]
  16. Guha A., Bach R., Konigsberg W., Nemerson Y. Affinity purification of human tissue factor: interaction of factor VII and tissue factor in detergent micelles. Proc Natl Acad Sci U S A. 1986 Jan;83(2):299–302. doi: 10.1073/pnas.83.2.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hedner U., Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest. 1983 Jun;71(6):1836–1841. doi: 10.1172/JCI110939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hedner U., Tengborn L. Management of haemophilia A with antibodies--the effect of combined treatment with factor VIII, hydrocortisone and cyclophosphamide. Thromb Haemost. 1985 Dec 17;54(4):776–779. [PubMed] [Google Scholar]
  19. Hruby M. A., Schulman I. Failure of combined factor VIII and cyclophosphamide to suppress antibody to factor VIII in hemophilia. Blood. 1973 Dec;42(6):919–923. [PubMed] [Google Scholar]
  20. Jackson C. M., Nemerson Y. Blood coagulation. Annu Rev Biochem. 1980;49:765–811. doi: 10.1146/annurev.bi.49.070180.004001. [DOI] [PubMed] [Google Scholar]
  21. Lusher J. M., Blatt P. M., Penner J. A., Aledort L. M., Levine P. H., White G. C., Warrier A. I., Whitehurst D. A. Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood. 1983 Nov;62(5):1135–1138. [PubMed] [Google Scholar]
  22. Lusher J. M., Shapiro S. S., Palascak J. E., Rao A. V., Levine P. H., Blatt P. M. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. N Engl J Med. 1980 Aug 21;303(8):421–425. doi: 10.1056/NEJM198008213030803. [DOI] [PubMed] [Google Scholar]
  23. Nemerson Y., Bach R. Tissue factor revisited. Prog Hemost Thromb. 1982;6:237–261. [PubMed] [Google Scholar]
  24. Nemerson Y. Regulation of the initiation of coagulation by factor VII. Haemostasis. 1983;13(3):150–155. doi: 10.1159/000214720. [DOI] [PubMed] [Google Scholar]
  25. Osterud B., Rapaport S. I. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5260–5264. doi: 10.1073/pnas.74.12.5260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Regnault V., Rivat C., Vallet J. P., Francois-Gerard C., Brochier G., Allain J. P. A potential new procedure for removing anti-factor VIII antibodies from hemophilic plasma. Thromb Res. 1987 Jan 1;45(1):51–57. doi: 10.1016/0049-3848(87)90256-8. [DOI] [PubMed] [Google Scholar]
  27. Roberts H. R. Hemophiliacs with inhibitors: therapeutic options. N Engl J Med. 1981 Sep 24;305(13):757–758. doi: 10.1056/NEJM198109243051308. [DOI] [PubMed] [Google Scholar]
  28. Sanders N. L., Bajaj S. P., Zivelin A., Rapaport S. I. Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood. 1985 Jul;66(1):204–212. [PubMed] [Google Scholar]
  29. Sjamsoedin L. J., Heijnen L., Mauser-Bunschoten E. P., van Geijlswijk J. L., van Houwelingen H., van Asten P., Sixma J. J. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med. 1981 Sep 24;305(13):717–721. doi: 10.1056/NEJM198109243051301. [DOI] [PubMed] [Google Scholar]
  30. White G. C., 2nd, Taylor R. E., Blatt P. M., Roberts H. R. Treatment of a high titer anti-factor-VIII antibody by continuous factor VIII administration: report of a case. Blood. 1983 Jul;62(1):141–145. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES